Drugs / Singletine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06160401 | Aug 2020 → Jan 2021 | — | Guangzhou JOYO Pharma Co., Ltd | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Singletine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06160401 ↗ |
| Known as | DC407 | “Safety, Tolerability and Pharmacokinetic Characteristics of Singletine(DC407) in Healthy Adult Subjects After Single and Multiple Doses” NCT06160401 ↗ |
| Route | Oral | “Singletine orally administered” NCT06160401 ↗ |